Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H16O6.2C22H29N3O6S |
Molecular Weight | 1315.464 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(C=CC=C2)C(CC3=C4C=CC=CC4=CC(C(O)=O)=C3O)=C1O.[H][C@]56SC(C)(C)[C@@H](N5C(=O)[C@H]6NC(=O)[C@H](N)C7=CC=CC=C7)C(=O)OCOC(=O)C(C)(C)C.[H][C@]89SC(C)(C)[C@@H](N8C(=O)[C@H]9NC(=O)[C@H](N)C%10=CC=CC=C%10)C(=O)OCOC(=O)C(C)(C)C
InChI
InChIKey=RYPIBFIQHKWKBM-WDPVPZODSA-N
InChI=1S/C23H16O6.2C22H29N3O6S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t;2*13-,14-,15+,18-/m.11/s1
Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMPICILLIN SODIUM Approved UseAmpicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.) |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129.5 μg/mL |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 h |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
AMPICILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (25%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
5 g 3 times / day multiple, intravenous Highest studied dose Dose: 5 g, 3 times / day Route: intravenous Route: multiple Dose: 5 g, 3 times / day Co-administed with:: Sulbactam(500 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
unhealthy, adult n = 9 Health Status: unhealthy Condition: Bacterial infections Age Group: adult Sex: M+F Population Size: 9 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
Other AEs: Injection site pain... Other AEs: Injection site pain Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Other AEs: Injection site pain, Creatine phosphokinase increased... Other AEs: Injection site pain (grade 3-4, 100%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40Creatine phosphokinase increased (100%) |
2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Other AEs: Injection site pain, Rash... Other AEs: Injection site pain (1%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160Rash (1%) Diarrhea (5%) Fatigue (3%) Chills (1%) Headache (1%) AST increased (3%) Bilirubin increased (1%) Creatinine increased (1%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Other AEs: Chest pain, Flatulence... Other AEs: Chest pain (5%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53Flatulence (5%) Diarrhea (10%) Injection site pain (5%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Other AEs: Injection site pain, Phlebitis... Other AEs: Injection site pain (0.8%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57Phlebitis (5.3%) Chest pain (0.8%) Diarrhea (6.8%) Vomiting (0.8%) Retention of urine (0.8%) Rash (0.8%) Epistaxis (0.8%) Edema (0.8%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Other AEs: Thrombophlebitis, Nausea... Other AEs: Thrombophlebitis (6.7%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155Nausea (6.7%) Diarrhea (6.7%) Rash (6.7%) Blood eosinophils increased (6.7%) AST increased (6.7%) ALT increased (13.3%) GGT increased (13.3%) Alkaline phosphatase increased (6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin rash | 25% Disc. AE |
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Injection site pain | 0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
|
Creatine phosphokinase increased | 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Injection site pain | grade 3-4, 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Bilirubin increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Chills | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Creatinine increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Headache | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Injection site pain | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Rash | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
AST increased | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Fatigue | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 5% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 10% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Flatulence | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Injection site pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Edema | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Epistaxis | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Injection site pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Rash | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Retention of urine | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Vomiting | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Phlebitis | 5.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Diarrhea | 6.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
ALT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
GGT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
AST increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Alkaline phosphatase increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Blood eosinophils increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Diarrhea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Nausea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Rash | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Thrombophlebitis | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 2.0 |
yes [Inhibition 1000 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Therapeutic efficacy of tobramycin--a clinical and laboratory evaluation. | 1975 Dec |
|
Hearing loss as a sequel to chloramphenicol and ampicillin treatment of Haemophilus influenzae meningitis. | 1976 |
|
Tone audiometry control of children treated for meningitis with large intravenous doses of ampicillin. | 1976 Nov |
|
Fresh vs aged benzylpenicillin on non-IgE responses in mice. | 1998 Jan |
|
Immunologic response to different determinants of benzylpenicillin, amoxicillin, and ampicillin. Comparison between urticaria and anaphylactic shock. | 1999 Sep |
|
Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons. | 2000 |
|
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection. | 2001 |
|
Superantigen antagonist peptides. | 2001 |
|
Effect of granulocyte-macrophage colony-stimulating factor on treatment of acute osteomyelitis. An experimental investigation in rats. | 2001 |
|
The frequency of silencing in Arabidopsis thaliana varies highly between progeny of siblings and can be influenced by environmental factors. | 2001 |
|
Enterobacter spp. infections complicating the course of HIV disease. | 2001 Apr |
|
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait. | 2001 Apr |
|
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia. | 2001 Apr |
|
The isolation and characterization of Campylobacter jejuni subsp. jejuni from domestic geese (Anser anser). | 2001 Apr |
|
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
An outbreak of Salmonella enteritidis infection in pygmy hogs (Sus salvanius). | 2001 Apr |
|
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2001 Apr 1 |
|
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate. | 2001 Feb |
|
Syntheses and hydrolysis of basic and dibasic ampicillin esters tailored for intracellular accumulation. | 2001 Feb |
|
Synergistic effect of gentamicin plus ampicillin on enterococci. | 2001 Feb |
|
Vibrio parahaemolyticus associated with cholera-like diarrhea among patients in North Jakarta, Indonesia. | 2001 Feb |
|
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. | 2001 Feb |
|
Resistance patterns of non-O157 Shiga toxin-producing Escherichia coli (STEC) strains isolated from animals, food and asymptomatic human carriers in Switzerland. | 2001 Feb |
|
[Streptococcus gallolyticus infections in racing pigeons, a literature review]. | 2001 Feb 1 |
|
Clostridium difficile--Associated diarrhea: A review. | 2001 Feb 26 |
|
Immunization with plasmid DNA expressing the caprine arthritis-encephalitis virus envelope gene: quantitative and qualitative aspects of antibody response to viral surface glycoprotein. | 2001 Feb 8 |
|
Shigella and Salmonella strains isolated from children under 5 years in Gaborone, Botswana, and their antibiotic susceptibility patterns. | 2001 Jan |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
Fetal and neonatal death from maternally acquired infection. | 2001 Jan |
|
Salmonella typhimurium-endocarditis secondary to an acquired environmental infection: a case report. | 2001 Jan |
|
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. | 2001 Jan |
|
In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. | 2001 Jan |
|
A suicide-substrate mechanism for hydrolysis of beta-lactams by an anti-idiotypic catalytic antibody. | 2001 Jan 26 |
|
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age]. | 2001 Jan-Feb |
|
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk. | 2001 Jan-Feb |
|
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. | 2001 Mar |
|
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test. | 2001 Mar |
|
Improved agar diffusion method for detecting residual antimicrobial agents. | 2001 Mar |
|
Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. | 2001 Mar |
|
Antimicrobial resistance in salmonellae from humans, food and animals in Spain in 1998. | 2001 Mar |
|
Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
Serogroups and antimicrobial susceptibility among Escherichia coli isolated from farmed mink (Mustela vison Schreiber) in Denmark. | 2001 Mar 20 |
|
Association between antibiotic resistance and the expression of Dr adhesin among uropathogenic Escherichia coli. | 2001 Mar-Apr |
|
Ureidopenicillins and risk of Clostridium difficile infection. | 2001 May |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. | 2001 May 15 |
|
The ddcA gene from Streptomyces fradiae encodes an extracellular beta-lactamase with penicillinase and cephalosporinase activities. | 2001 Nov 30 |
|
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. | 2001 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ampicillin.html
Ampicillin Dosage and Administration
This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only.
Infections of the respiratory tract and soft tissues.
Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.
Urethritis in males due to N. gonorrhoeae.
Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.
In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.
The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate.
Bacterial Meningitis
Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.
Septicemia
Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14195635
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39030-72-3
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
5Z5TRG74EY
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
20055543
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL323354
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY | |||
|
C73835
Created by
admin on Fri Dec 15 16:24:14 GMT 2023 , Edited by admin on Fri Dec 15 16:24:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD